Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?
Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.
Pharma & Biotech